Phase 2 N=94 Proactive Outreach for Smoking Treatment
Smoking, Tobacco · Mental Illness
Primary: Study 3: Smoking Abstinence — 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=114 N-acetylcysteine for Tobacco Use Disorder
Nicotine Dependence · Smoking
Primary: Number of Participants With Biochemically-verified Abstinence From Smoking on Days 1-3 of the Protocol. — 8; 6 Participants
N/A N=67 Clinical Trial Tobacco Marijuana
Cannabis Use Disorder · Tobacco Use Disorder
Primary: Tobacco Quit Attempts — 13; 17 Participants — p== 0.33
Phase 4 N=323 A Smart Approach to Treating Tobacco Use Disorder in Persons Living With HIV
Tobacco Use Cessation
Primary: Self Reported Reduction in Average Cigarettes Smoked Per Day at 12 Weeks — 5.2; 4.9 cigarettes per day
Phase 4 N=90 Tobacco Use Treatment in Cancer Patients
Smoking, Cigarette
Primary: Smoking 7-Day Point Prevalence at 12 Weeks — 2; 2; 3 Participants
Phase 2 N=326 Low Nicotine Content Cigarettes in Vulnerable Populations: Opioid Use Disorder
Tobacco Use Disorder
Primary: Number of Cigarettes Smoked Per Day — 22.54; 14.32; 11.76; 7.63 cigarettes per day
Phase 4 N=7 Varenicline for Co-occurring Cannabis and Tobacco Use
Cannabis Dependence · Tobacco Dependence
Primary: Enrollment Rate — 7 Participants
Phase 2 N=10 The Effects of Sedatives on Tobacco Use Disorder
Tobacco Use Disorder
Primary: Side Effects — 1.3; 1.4 score on a scale
Phase 4 N=181 Cannabis and Tobacco Co-use Study
Tobacco Use Disorder
Primary: Number of Participants With Biologically Verified 7-day Point Prevalence Tobacco Abstinence at the End of Treatment (Week 12) — 30; 40; 36; 42 Participants
Phase 2 N=326 Low Nicotine Content Cigarettes in Vulnerable Populations: Affective Disorders
Tobacco Use Disorder
Primary: Cigarettes Per Day — 22.54; 14.32; 11.76; 7.63 cigarettes per day
Phase 2 N=72 Varenicline Treatment for Cannabis Use Disorder
Substance Use Disorder
Primary: Cannabis Withdrawal Symptoms During Active Treatment — 2.23; 3.94; 2.59; 4.07 score on a scale
N/A N=224 Treating Tobacco Dependence in Inpatient Psychiatry - 1
Tobacco Use Cessation · Tobacco Use Disorder
Primary: 7 Day Point Prevalence of Cigarette Abstinence — 3; 14; 6; 14 Participants — p=0.018
N/A N=137 Varenicline and Motivational Advice for Smokers With Substance Use Disorders
Smoking Cessation · Nicotine Dependence
Primary: 7-day Point-prevalence Smoking Abstinence — 2; 10 participants — p=<0.05
N/A N=5,123 Proactive Tobacco Treatment for Veterans
Smoking Cessation · Smoking Tobacco
Primary: Self-reported, Smoking Abstinence Rate: 6-month Prolonged Abstinence — 10.9; 13.5 percentage of participants — p=.02
N/A N=832 Testing an Organizational Change Model to Address Smoking in Mental Healthcare
Nicotine Dependence
Primary: Client Reported Tobacco Medications — 48; 28; 62; 24 Participants
Phase 2 N=11 Suvorexant to Reduce Symptoms of Nicotine Use
Smoking Cessation
Primary: Stress as Assessed by a Visual Analog Scale (VAS) for Stress — 3.4; 3 score on a scale
Phase 3 N=52 Highdose Nicotine Patch Therapy for Smokeless Tobacco Use
Smokeless Tobacco Use
Primary: End of Treatment (Week 8) Point Prevalence Abstinence — 11; 6 participants — p=0.05
Phase 4 N=226 Stress Neuroadaptation in Tobacco Dependence
Nicotine Dependence
Primary: Overall Stressor Reactivity — 25.1; 22.5; 32.3; 16.9 microvolts
Phase 4 N=30 Tobacco Cessation Treatment Preferences Among Veteran Smokers
Tobacco Use
Primary: Number of Participants Who Report Post-treatment Satisfaction — 15; 10 Participants
N/A N=685 Improving Tobacco Treatment Rates for Cancer Patients Who Smoke
Cancer · Tobacco Use · Smoking
Primary: Intervention Ordering Rate — 113; 60 Participants
Phase 2 N=174 UH3 Varenicline for Cannabis Use Disorder
Cannabis Use Disorder
Primary: Efficacy of Varenicline vs. Placebo for Reducing Total Number of Weekly Cannabis Use Sessions — 10.3; 11.6; 9.4; 11.7 number of weekly use sessions
Phase 4 N=179 Smoking Tobacco and Drinking Study
Smoking · Heavy Episodic Drinking
Primary: Number of Participants With Reported 7-day Point Prevalence Abstinence at 3 Months — 3; 4 Participants
Phase 2 N=232 UW Withdraw From Tobacco Study
Tobacco Dependence
Primary: Change in Total Score on Wisconsin Smoking Withdrawal Scale2 Long (WSWS2-L) — 2.64; 2.36; 2.29; 2.69 score on a scale
N/A N=2,057 The Tobacco, Alcohol, Prescription Medication and Other Substances Tool
Substance Use Disorder
Primary: Diagnostic and Statistical Manual-5 (DSM-5) Alcohol Use Disorder Diagnosis Measured by the Modified World Mental Health Composite International Diagnostic Interview…
Early Phase 1 N=7 Ketamine and Motivational Enhancement Therapy for the Treatment of Tobacco Use Disorder
Tobacco Use · Smoking Cessation · Nicotine Dependence
Primary: Feasibility of Ketamine Treatment for Tobacco Use Disorder — 7 Participants
N/A N=51 Health-Kit Enabled Mobile App for Tobacco Cessation
Cigarette Smoking
Primary: Psychosocial Expectancies (PROMIS Smoking Initiative) Patient Reported Outcome — 12.7; 13.6 score on a scale — p=0.17
N/A N=148 Implementation of Genomics in Substance Use Disorder Treatment
Tobacco Use Disorder · Smoking Cessation · Tobacco Use Cessation
Primary: Change in Use of Smoking Cessation Pharmacotherapy in Past 30 Days — 11; 9; 9; 2 Participants
N/A N=956 Evaluation of Tobacco Treatment Strategies for Inpatient Psychiatry
Tobacco Dependence
Primary: Number of Participants Who Quit Smoking at 3, 6, 12, and 18 Months — 13; 70; 63; 15 Participants
N/A N=136 Reduced Nicotine Content Cigarettes and Tobacco Switching Behaviors
Tobacco Addiction · Dual Tobacco Use
Primary: Number of Days Using Alternative Products — 14; 26; 20 Number of days
Phase 2 N=775 Project 2, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in Opioid Abusers
Tobacco Use Disorder
Primary: Cigarettes Per Day (CPD) — 25.28; 19.95; 17.74 cigarettes per day — p=<0.0001